Table 1 Comparison of clinical baseline data between SYNTAX low and medium/high risk group [n(%),M(P25--P75)]
Item | Low-risk group (0–22) | Medium/high risk group (≥23) | p | |
|---|---|---|---|---|
n | 331 | 65 | ||
Gender | Male | 224(67.7) | 50(76.9) | 0.140 |
Female | 107(32.3) | 15(23.1) | ||
In-hospital ventricular fibrillation | 1(0.3) | 0 | 1.000 | |
In-hospital ventricular tachycardia | 2(0.6) | 1(1.5) | 0.417 | |
In-hospital atrial fibrillation | 6(1.8) | 3(4.6) | 0.170 | |
In-hospital heart failure | 52(15.7) | 18(27.7) | 0.021 | |
Hypertension | 211(63.7) | 40(61.5) | 0.736 | |
Diabetes | 62(18.7) | 17(26.2) | 0.171 | |
CHD history | 61(18.4) | 10(15.4) | 0.559 | |
Myocardial infarction history | 22(6.6) | 6(9.2) | 0.432 | |
PCI history | 18(5.4) | 6(9.2) | 0.255 | |
Smoking history | 192(58.0) | 35(53.8) | 0.535 | |
Age(years old) | 58.84 ± 10.27 | 60.23 ± 9.83 | 0.340 | |
BMI(kg/m2) | 25.37 ± 3.93 | 24.83 ± 4.39 | 0.349 | |
Ejection fraction(%) | 58.87 ± 10.83 | 56.12 ± 10.90 | 0.103 | |
ApoB/ApoA1 | High risk | 9(2.7) | 6(9.2) | 0.023 |
Low risk | 322(97.3) | 59(90.8) | ||
ApoB/ApoA1 | 0.91(0.71–1.04) | 0.94(0.76–1.05) | 0.152 | |
TG(mmol/l) | 1.73(1.0–2.13) | 1.78(1.14–2.30) | 0.267 | |
LDL-c(mmol/l) | 3.13(2.46–3.65) | 3.17(2.46–3.70) | 0.727 | |
Non HDL-c(mmol/l) | 3.5(2.77–4.10) | 3.62(2.94–4.05) | 0.464 | |
Hb(g/L) | 140.81(131–153) | 140.5(129–155) | 0.976 | |
PLT(× 109/L) | 205.2(166–238) | 193.01(157.5–227.5) | 0.182 | |
HCT(L/L) | 0.93(0.39–0.45) | 0.42(0.39–0.46) | 0.768 | |
LM | 16(4.8) | 16(24.6) | < 0.001 | |
PLAD | 216(65.3) | 55(84.6) | < 0.001 | |
MLAD | 173(52.3) | 38(58.5) | 0.415 | |
RCX | 224(67.7) | 56(86.2) | < 0.001 | |
RCA | 267(80.7) | 59(90.8) | 0.052 | |
RAM | 5(1.5) | 2(3.1) | 0.323 | |
Number of lesions treated | 1.38 ± 0.66 | 1.55 ± 0.73 | 0.032 | |
Number of stents implanted | 1.49 ± 0.90 | 1.59 ± 1.0 | 0.345 | |
Maximum stent diameter(mm) | 3.32 ± 0.49 | 3.24 ± 0.46 | 0.134 |